Jump to content

Page values for "Methotrexate"

"Medicines" values

1 row is stored for this page
FieldField typeValue
genericStringMethotrexate
brandStringTrexall, Otrexup, Rasuvo, Xatmep, Rheumatrex (discontinued)
structureFile
classesList of String, delimiter: ,[[:Category:Antifolates|Antifolate]] [[:Category:DMARDs|DMARD]] [[:Category:Antineoplastics|Antineoplastic]] [[:Category:Immunosuppressants|Immunosuppressant]]
mechanismString
usesString'"`UNIQ--vote-000007C1-QINU`"', '"`UNIQ--vote-000007C2-QINU`"', '"`UNIQ--vote-000007C3-QINU`"', '"`UNIQ--vote-000007C4-QINU`"', '"`UNIQ--vote-000007C5-QINU`"', '"`UNIQ--vote-000007C6-QINU`"', '"`UNIQ--vote-000007C7-QINU`"'
starting_doseStringRheumatologic: 7.5-15 mg PO or SC '''once weekly''' (not daily — daily dosing is a recognized fatal error); folic acid 1 mg PO daily on non-MTX days; oncology dosing is far higher and indication-specific
preparationsString2.5 mg tablets; 10-50 mg/mL injection; pre-filled subcutaneous autoinjectors (Otrexup, Rasuvo); 2.5 mg/mL oral solution (Xatmep)
fda_maxStringRheumatologic ~25 mg/week; oncology indication-specific
pill_idText
routesList of String, delimiter: ,Oral subcutaneous intramuscular IV intrathecal
onsetStringRheumatologic effect at 4-8 weeks; ectopic resolution over 2-3 weeks
durationStringOnce-weekly dosing in rheumatology
halflifeString3-10 hours (low dose); 8-15 hours (high dose); much longer in third-space accumulation (pleural effusion, ascites)'"`UNIQ--ref-000007C8-QINU`"'
bioavailabilityString60-70% PO at low doses; saturable at high doses (parenteral routes preferred above 15-25 mg/week)'"`UNIQ--ref-000007C9-QINU`"'
pregnancyString'''Contraindicated in pregnancy''' (Category X); abortifacient and teratogenic. Discontinuation 3-6 months before conception is standard.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup>
legalString[[USLegal:Prescription only|Rx-only]] in US